About
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Current Value
$16.751 Year Return
Current Value
$16.751 Year Return
Key Details
Market Cap
$1.14B
P/E Ratio
-7.01
1Y Stock Return
-56.66%
1Y Revenue Growth
1.99%
Dividend Yield
0.00%
Price to Book
1.5
Strategies that include CLDX
Double maintains 2 strategies that include CLDX - Celldex Therapeutics, Inc.
Growth at a Fair Price
High risk
$1,000
These stocks above $1B in Market Cap are modestly valued (PE below 15) but are in the top 20% of stocks for revenue growth over the past 5 years. We weight them by market cap.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
195
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to CLDX
The stocks that are correlated to CLDX - Celldex Therapeutics, Inc. are DNLI, BEAM, KYMR, CELC, NTLA
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 47.48% | $1.86B | -32.65% | 0.00% | |
| 47.26% | $1.64B | -43.30% | 0.00% | |
| 45.41% | $1.54B | -34.63% | 0.00% | |
C CELCCelcuity, Inc. | 44.32% | $334.88M | -55.53% | 0.00% |
| 44.18% | $713.23M | -72.41% | 0.00% | |
| 43.88% | $290.64M | -55.37% | 0.00% | |
| 41.66% | $606.82M | -22.75% | 0.00% | |
| 41.57% | $981.56M | +7.69% | 0.00% | |
| 41.23% | $2.69B | -38.11% | 0.00% | |
P PRTAProthena Corp. Plc | 41.06% | $609.32M | -51.33% | 0.00% |
S SDGRSchrödinger, Inc. | 40.92% | $1.38B | -27.56% | 0.00% |
| 40.60% | $2.08B | -40.69% | 0.00% | |
A ALTAltimmune, Inc. | 40.49% | $343.48M | -49.89% | 0.00% |
I IMNMImmunome, Inc. | 40.39% | $542.57M | -69.20% | 0.00% |
| 40.33% | $6.11B | +9.06% | 0.00% | |
| 40.03% | $5.13B | -0.20% | 0.00% | |
| 40.00% | $592.86M | -77.74% | 0.00% | |
Z ZYMEZymeworks, Inc. | 39.67% | $824.23M | +21.64% | 0.00% |
| 39.14% | $1.05B | +28.16% | 0.00% | |
| 38.99% | $1.12B | +20.54% | 1.54% | |
ETF's related to CLDX
The ETFs that are correlated to CLDX - Celldex Therapeutics, Inc. are XBI, GNOM, IBB, PBE, CPRJ
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
X XBISPDR Biotech ETF | 57.33% | $5.06B | 0.35% |
| 52.09% | $48.48M | 0.5% | |
| 50.49% | $5.70B | 0.45% | |
| 48.94% | $229.13M | 0.58% | |
| 47.72% | $48.65M | 0.69% | |
| 47.60% | $987.53M | 0.75% | |
| 47.51% | $809.63M | 0.6% | |
| 44.02% | $110.09M | 0.6% | |
| 43.58% | $10.93B | 0.24% | |
| 43.51% | $11.24B | 0.07% | |
| 43.38% | $63.84B | 0.19% | |
| 42.67% | $362.92M | 0.35% | |
| 41.82% | $320.39M | 0.79% | |
| 41.81% | $11.04B | 0.24% | |
| 41.72% | $521.56M | 0.2% | |
| 41.43% | $16.19B | 0.04% | |
| 41.30% | $842.66M | 0.6% | |
| 41.22% | $158.44M | 0.35% | |
| 41.18% | $141.74M | 0.5% | |
| 41.04% | $135.35M | 0.79% | |
News
Yahoo
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex websit
Yahoo
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation. Th
Finnhub
HAMPTON - Celldex Therapeutics, Inc. announced today positive data on measurements of disease control and quality of life from the Company's Phase 2 barzolvolimab studies in patients with chronic...
Yahoo
Celldex Therapeutics ( NASDAQ:CLDX ) Full Year 2024 Results Key Financial Results Net loss: US$157.9m (loss widened by...
Yahoo
Celldex (CLDX) delivered earnings and revenue surprises of 5.33% and 24.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds